share_log

Morgan Stanley Maintains Equal-Weight on Senti Biosciences, Lowers Price Target to $3

Benzinga Real-time News ·  Jan 27, 2023 10:35

Morgan Stanley analyst Michael Ulz maintains Senti Biosciences (NASDAQ:SNTI) with a Equal-Weight and lowers the price target from $7.5 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment